anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods are provided for the synthesis of poly(ethylene oxide) ("PEO") star macromolecules including functionalizable groups. In one embodiment, a core molecule including a plurality of dendritic branches or having a comb structure, and including a plurality of accessible reactive groups is reacted with functionalizable poly(ethylene oxide) ("PEO") molecules. The functionalizable poly(ethylene oxide) molecules include a reactive group capable of reacting with the reactive group on the core molecule, and a functionalizable group capable of being chemically modified, which optionally is protected. In the reaction, the PEO molecules are covalently attached to the core molecule, to form a PEO star macromolecule with terminal functionalizable groups. Preferably, the functionalizable PEO is a heterofunctional linear PEO which includes the reactive group at one terminus and the functionalizable group at the other terminus. The functionalizable groups on the PEO molecules then may be deprotected if necessary, and then further derivatized, for example, by the attachment of a biologically active molecule or polymer thereof.
PURPOSE OF REVIEW: This review highlights the difficulties in diagnosing and treating persons with a prior history of cryptococcal meningitis who improve but suffer from a recurrence of symptoms. This scenario is well known to those who frequently care for patients with cryptococcal meningitis but is not well understood. We highlight major gaps in knowledge.
RECENT FINDINGS: We recently summarized our experience with 28 persons with paradoxical immune reconstitution inflammatory syndrome (IRIS) and 81 persons with microbiological relapse. CD4 count and cerebrospinal fluid white blood cell count were higher in IRIS than relapse but neither was reliable enough to routinely differentiate these conditions. Second-episode cryptococcal meningitis remains a difficult clinical scenario as cryptococcal antigen, while excellent for initial diagnosis has no value in differentiating relapse of infection from other causes of recurrent symptoms. Updated research definitions are proposed and rapid, accurate diagnostic tests are urgently needed.
Multiple component grafts are provided for treatment of tissue defects and comprise two or more components, each of which is a tissue-derived matrix and at least two of which are derived from different types of tissue. For example, a first component may be a matrix derived from cartilage tissue such as cartilage fibers with or without viable cells, cartilage particles with or without viable cells, or combinations of any two or more such cartilage-derived matrices. A second component may be a matrix derived from bone tissue such as mineralized or demineralized cortical bone fibers, viable cancellous bone matrix (e.g., cryopreserved or lyophilized chips, particulates, powder, sheets, putty, flowable fluid, etc.), demineralized or demineralized cancellous bone matrix (chips, particulates, powder, sheets, putty, flowable fluid, etc.), or combinations of any two or more of such bone-derived matrices. Also provided are methods for making and using such multiple component grafts.
A new preparation is proposed, which prevents the development of resistance to fluorochinolon and acts in synergy. It is applied through the mouth, dissolved in drinking water or neat, sprayed into the mouth by a syringe. The preparation is an aqueous solution containing active components. A new preparation is proposed, which prevents the development of resistance to fluorochinolon and acts in synergy. It is applied through the mouth, dissolved in drinking water or neat, sprayed into the mouth by a syringe. The preparation is an aqueous solution containing active components, including the following: In 5.1-30% concentration: 6-fluoro-7-piperazinyl-4-chinolon [fluorochinolon] and or their salts produced with acid, In 2.6-15% concentration: chitosan-sulphate, In 0.1-50% concentration: a hydroxyl-carbonic acid and/or amino-acid, and according to requirements, additives in concentrations of 0.1-50%.
A novel quinazoline derivative is provided to inhibit cancer cell growth caused by epithelial growth factor and its mutants without any side effect selectively and efficiently. And a pharmaceutical composition for inhibiting cancer cell growth comprising the same is provided. A quinazoline derivative is represented by the formula(1). In the formula(1), R1 is C1-6 alkoxy substituted with a C1-6 alkoxy or heterocyclic group, wherein the heterocyclic group is a 5 or 6-membered heteroaromatic or non-aromatic group containing one to four of the elements selected from the group consisting of N, O and S; R2 is H or phenyl substituted with halogen; and A is -C(=O)- or -CH2-. A pharmaceutical composition for inhibiting the growth of cancer cells comprises the quinazoline derivative or a pharmaceutically acceptable salt thereof as an active ingredient. The composition further comprises an anticancer agent selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, antimetabolites, antibiotics, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological reaction modifiers, antihormonal agents and antiandrogen.
INTRODUCTION: Hemorrhagic shock (HS) poses a life-threatening condition with the lungs being one of the most susceptible organs to its deleterious effects. Extracellular cold-inducible RNA binding protein has emerged as a pivotal mediator of inflammation, and its release has been observed as a case of HS-induced tissue injury. Previous studies unveiled a promising engineered microRNA, designated PS-OMe miR130, which inhibits extracellular cold-inducible RNA binding protein, thereby safeguarding vital organs. In this study, we hypothesized that PS-OMe miR130 serves as a protective shield against HS-induced lung injury by curtailing the overzealous inflammatory immune response.
METHODS: Hemorrhagic shock was induced in male C57BL6 mice by withdrawing blood via a femoral artery cannula to a mean arterial pressure of 30 mm Hg for 90 minutes. The mice were resuscitated with twice the shed blood volume with Ringer's lactate solution. They were then treated intravenously with either phosphate-buffered saline (vehicle) or 62.5 nmol PS-OMe miR130. At 4 hours later, blood and lungs were harvested.
RESULTS: Following PS-OMe miR130 treatment in HS mice, a substantial decrease was observed in serum injury markers including aspartate aminotransferase, alanine transaminase, lactate dehydrogenase, and blood urea nitrogen. Serum interleukin (IL)-6 exhibited a similar reduction. In lung tissues, PS-OMe miR130 led to a significant decrease in the messenger RNA expressions of pro-inflammatory cytokines (IL-6, IL-1β, and tumor necrosis factor α), chemokines (keratinocyte-derived chemokine and macrophage inflammatory protein 2), and an endothelial injury marker, E-selectin. PS-OMe miR130 also produced substantial inhibition of lung myeloperoxidase activity and resulted in a marked reduction in lung injury as evidenced by histological evaluation. This was further confirmed by the observation that PS-OMe miR130 significantly reduced the presence of lymphocyte antigen 6 family member G-positive neutrophils and terminal deoxynucleotidyl transferase dUTP nick end labeling-positive apoptotic cells.
CONCLUSION: PS-OMe miR130 emerges as a potent safeguard against HS-induced lung injury by effectively inhibiting pro-inflammation and injuries, offering a promising therapeutic strategy in such critical clinical condition.
Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
The present invention relates to a lactobacillus, a nucleotide sequence for lactobacillus, and primers for nucleotide sequence. The lactobacillus is Lactobacillus paracasei subsp. paracasei PAN 101 having the nucleotide sequence of SEQ ID NO:1, and deposited in Agricultural Research Culture Collection (NRRL) in November 13, 2009, wherein the accession number of Lactobacillus paracasei subsp. paracasei PAN 101 is NRRL B-50335. In the present invention, the nucleotide sequence for Lactobacillus paracasei subsp. paracasei PAN 101 and the primers for the nucleotide sequence are proposed, so as to facilitate the person skilled in lactobacillus filed capable of carrying out the strain identification of the Lactobacillus paracasei subsp. paracasei PAN 101 according to the present invention. Moreover, the person skilled in lactobacillus filed can also complete the strain identification of the Lactobacillus paracasei subsp. paracasei PAN 101 by using DNA molecular marker technology, without culturing isolated Lactobacillus strain or live Lactobacillus bacteria.
CAE is an adjunctive (to standard medication treatment) behavioral intervention delivered virtually (real-time one on one video-conferencing) in 6 individual sessions. All participants will receive content from the 4 currently existing CAE modules delivered over a 6-session series spaced out over approximately 6-10 weeks. The material from the 4 modules will be broken down into predetermined sub-sections and delivered in 6 sessions. The modules themselves are delivered in sections (thematic units within the module) and do not correspond to a specific session. The 4 CAE modules are Psychoeducation, Communication with Providers, Medication Routines, and Substance Use.
Evidence suggests an association between obesity and the risk for cardiomyopathy development; however, robust evidence is still lacking. In this study we sought to explore the relationship of obesity with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) and possible interactions with sex using large-scale epidemiological real-world data. We analysed data from the Nationwide Inpatient Sample of US hospitalisations for the years 2015-2019. There were a total of 46 934 admissions with diagnosis of HCM and 170 924 with DCM. There was a significant interaction between cardiomyopathies' diagnosis with sex and age subgroups; the rates of both DCM and HCM increased with age (p < .001 for both); DCM diagnosis was significantly higher in males compared with females (0.85% vs. 0.35%, p < .001). After adjustment for age, sex, race and presence of arterial hypertension there was a significant stepwise positive association between obesity and the population rates of both cardiomyopathy subtypes. For hospitalised patients with a body mass index (BMI) ≥30 kg/m2 there was an odds ratio (OR) of 1.68 (95% CI: 1.55-1.81, p < .001) for HCM and OR = 1.82 (95% CI: 1.79-1.84, p < .001) for DCM. More importantly, the positive relationship between a cardiomyopathy diagnosis (HCM or DCM) with increasing BMI was driven by the male sex (p < .001 for both) and it was non-significant in females. The findings from this nationwide observational analysis support a sexual dimorphism in the relationship between obesity and HCM or DCM, which should be further investigated.
PURPOSE:To provide a pimple-preventive cosmetic composition having excellent antibacterial power to acneform bacteria and free from side-effect to cause dermatic allergy in contrast to conventional sterilizing agent. CONSTITUTION:The objective pimple-preventive cosmetic composition contains 0.001-5.0wt.% (preferably 0.01-2.5wt.%) of a water-extract and/or an organic solvent extract of a plant of the genus Caesalpinia as an active component. The plant of the genus Caesalpinia is e.g. Caesalpinia sappan, Caesalpinia crista, Caesalpinia magnifoliolata, Caesalpinia minax, Caesalpinia sepiaria and Caesalpinia sepiaria var. pubscens. Caesalpinia sappan is most preferable among the above plants because an extract having especially excellent antibacterial power to acneform bacteria is obtained from the plant. The extraction solvent is e.g. benzene, ethyl ether, chloroform, ethyl acetate, acetone, methanol, ethanol or butyl alcohol.
Inherited cardiovascular conditions are significant causes of sudden cardiac death in the young (SCDY), making their investigation using molecular autopsy and prevention a public health priority. However, the molecular autopsy data in Chinese population is lacking. The 5-year result (2017-2021) of molecular autopsy services provided for victims of SCDY (age 1-40 years) was reviewed. The outcome of family cascade genetic screening and clinical evaluation was reviewed. A literature review of case series reporting results of molecular autopsy on SCDY in 2016-2023 was conducted. Among the 41 decedents, 11 were found to carry 13 sudden cardiac death (SCD)-causative genetic variants. Likely pathogenic (LP) variants were identified in the DSP, TPM1, TTN, and SCN5A genes. Cascade genetic testing identified four family members with LP variants. One family member with familial TPM1 variant was found to have hypertrophic cardiomyopathy upon clinical evaluation. This study provided insight into the genetic profile of molecular autopsy in a Chinese cohort of SCDY. The detection of important SCD-causative variants through molecular autopsy has facilitated family cascade screening by targeted genetic testing and clinical evaluation of at-risk family members. A literature review of the current landscape of molecular autopsy in the investigation of SCDY was conducted.
There is disclosed novel  Phellinus linteus Yoo.  This mushroom is identified as novel as analyzed by restriction fragment length polymorphism and by microbiological features. A polysaccharide substance isolated from the fruiting bodies or mycelia the strain and other Phellinus spp. has an anticancer activity by inciting the cytotoxicity of T-cells and the antibody forming potency of B-cells. Also, the polysaccharide substance shows a potent activity against cancer metastasis. The polysaccharide substance, which can stimulate the immunity of the body, may be effective in the prophylaxis and treatment of immune-related diseases, such as cancers and AIDS, and in the study on the basic mechanism of the diseases.
The Center for Disease Control and Prevention estimates that 75% of reported cases of traumatic brain injury (TBI) are mild, where chronic pain and depression are 2 of the most common symptoms. In this study, we used a murine model of repeated mild TBI to characterize the associated pain hypersensitivity and affective-like behavior and to what extent microglial reactivity contributes to these behavioral phenotypes. Male and female C57BL/6J mice underwent sham or repeated mild traumatic brain injury (rmTBI) and were tested for up to 9 weeks postinjury, where an anti-inflammatory/neuroprotective drug (minocycline) was introduced at 5 weeks postinjury in the drinking water. Repeated mild traumatic brain injury mice developed cold nociceptive hypersensitivity and negative affective states, as well as increased locomotor activity and risk-taking behavior. Minocycline reversed negative affect and pain hypersensitivities in male but not female mice. Repeated mild traumatic brain injury also produced an increase in microglial and brain-derived neurotropic factor mRNA transcripts in limbic structures known to be involved in nociception and affect, but many of these changes were sex dependent. Finally, we show that the antiepileptic drug, gabapentin, produced negative reinforcement in male rmTBI mice that was prevented by minocycline treatment, whereas rmTBI female mice showed a place aversion to gabapentin. Collectively, pain hypersensitivity, increased tonic-aversive pain components, and negative affective states were evident in both male and female rmTBI mice, but suppression of microglial reactivity was only sufficient to reverse behavioral changes in male mice. Neuroinflammation in limbic structures seems to be a contributing factor in behavioral changes resulting from rmTBI.
The invention provides a DLL3 monoclonal antibody, belonging to the field of tumor immunotherapy drugs. The DLL3 monoclonal antibody comprises fragments of CDR1, CDR2 and CDR3, wherein the amino acid sequence of CDR1 is SEQ ID NO.9, the amino acid sequence of CDR2 is SEQ ID NO.10, and the amino acid sequence of CDR3 is SEQ ID NO. 11; or the amino acid sequence of the CDR1 is SEQ ID NO.12, the amino acid sequence of the CDR2 is SEQ ID NO.13, and the amino acid sequence of the CDR3 is SEQ ID NO. 14; or the amino acid sequence of the CDR1 is SEQ ID NO.15, the amino acid sequence of the CDR2 is SEQ ID NO.16, and the amino acid sequence of the CDR3 is SEQ ID NO. 17. The DLL3 monoclonal antibody has a short sequence, can well recognize DLL3, has strong binding capacity to DLL3, can recognize DLL3 expressed in tumor cells when being used for preparing anti-tumor immunotherapy drugs, can be well combined with the tumor cells, and further has a good targeted anti-tumor effect. The invention provides a new choice for clinically resisting tumors and has good application prospect.
Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
PURPOSE:To provide an industrial process by which lanolin fatty acids are separated into a hydroxy fatty acid component and a nonhydroxy fatty acid component both reduced in animal odor and color strength; and to provide uses of these components in a cosmetic and an external-use medical preparation. CONSTITUTION:Lanolin fatty acids are treated with boric acid to convert the hydroxy fatty acids contained therein into boric esters. The resulting mixture is distilled under a reduced pressure to separated the esters from nonhydroxy fatty acids (a), which are purified. The esters are then hydrolyzed and distilled under a reduced pressure to obtain an alpha-hydroxy fatty acid component (b) and an omega-hydroxy fatty acid component (c). The cosmetic and external-use medical preparation each contains as an active ingredient the above obtained acids (a), (b), and/or (c). Thus, desired lanolin fatty acids are easily and efficiently produced on an industrial scale as lightly colored, almost odorless products. They are utilizable in the medical and cosmetic fields, etc.
OBJECTIVES. To evaluate whether Magnetic Resonance (MR) helps in predicting the risk of Intracranial Hemorrhage (ICH-OA) in patients with ischemic stroke who will receive Oral Anticoagulants (OA) for the secondary prevention of stroke. By allowing the detection and quantification of leukoaraiosis and microbleeding, MR aids in the assessment of hypertensive and/or amyloid angiopathy, two findings that may increase the risk of ICH-OA. The study of these and other known variables associated with the risk of ICH-OA will improve the selection of patients to be treated with OA. METHODOLOGY. A prospective, observational, multicentric study of 1000 patients with stroke, older than 65 y, candidates to receive OA indefinitely. The primary end-point is ICH-OA. A MR will be performed before starting the treatment, in which we will evaluate the presence and degree of leukoaraiosis (Fazekas's scale) and microbleeding (BOMBS scale). A visit will be scheduled at the first month after inclusion, and thereafter the patient will be followed-up during 2 years with phone interviews, to evaluate the appearance of the primary end-point. We will register data about demographics, vascular risk factors, anticoagulation, MR, echocardiography and co-morbidity. With those variables associated with ICH-OA in the univariate analyses, a regression analysis will be performed, in which ICH-OA will be the dependent variable. Finally, each independent predictive variable will receive a score to elaborate a predictive model of ICH-OA.
Background: Veterans smoke at a higher rate (30%) than the U.S. adult population (21%), and veterans with PTSD have even higher rates of smoking (53-66%). Evidence has shown that any tobacco dependence treatment strategy must be integrated in the health care system because consistent and effective delivery of tobacco cessation requires coordinated interventions. Persistent tobacco users typically cycle through multiple periods of relapse and remission. Veterans with PTSD (279,256 in 2005) who are treated for smoking cessation may need more comprehensive aid to be successful. Failure to appreciate the chronic nature of tobacco dependence may impede comprehensive and consistent treatment. Care management using telehealth has been shown to improve access to care while reducing costs for veterans with chronic diseases and has the potential to coordinate smoking cessation with care for other chronic diseases. Nurses have successfully managed chronic diseases using telehealth by focusing on increasing self-management, positive behaviors and knowledge. Nurses are vital to increasing the level of support in the community through education and motivation and by responding to medical events in order to improve veterans' health.

Objectives: The study is designed to determine if adding motivational counseling and care management using the PTSD Health Buddy to usual care improves smoking quit rates of veterans with PTSD. Specific Aims are to compare: 1) self-reported quit attempts, progression through the stages of change, and quit rates, 2) patient perception of care coordination, and 3) changes in PTSD symptoms in veteran smokers with PTSD who receive a nurse-driven telephonic motivational counseling intervention triggered by responses to stage-based smoking cessation questions in addition to usual care to those who receive usual care only.
This is a multi-center, prospective, non-inferior, randomized controlled clinical study. The sick individuals and their families participating in the trial voluntarily participate and sign the "informed consent" under the premise of fully understanding the treatment plan; The treatment plan was approved by the hospital ethics committee.

A total of 152 patients from six centers nationwide will be enrolled starting from the date when the center's ethics are officially approved. The qualified recipients of donor kidney transplantation were randomly assigned 1:1 to the control group and the experimental group. The control group was treated with glucocorticoid + MPA+ tacrolimus for 12 months, and the experimental group was treated with glucocorticoid +MZR+ tacrolimus for 12 months. All subjects were followed up on the day of renal transplantation, at 1, 2 weeks and 1, 2, 3, 6, 9 and 12 months after the operation: history collection, incidence of acute rejection, survival rate of recipients, survival rate of transplanted kidney, liver and kidney function, blood routine and urine routine; Cytomegalovirus (CMV)-DNA and BK virus (BKV)-DNA copy levels were detected in blood at 1, 3, 6, 9, and 12 months after renal transplantation to assess CMV and BKV infection. Adverse reactions were recorded during follow-up.
PROBLEM TO BE SOLVED: To use an active ingredient comprising a specific compound or its pharmaceutically permissible salt as an incremental agent of recognition, etc., useful for treatment for Alzheimer's disease or disturbance of memory caused by senility. SOLUTION: Darifenacin, e.g. 3-(s)-(-)-(1-carbamoyl-1,1- diphenylmethyl)-1-[2-(2,3-dihydroxybenzofuran-5-yl)ethyl]pyrrolidine or its pharmaceutically permissible salt is used for a production of a remedy for disturbance of recognition, etc. A daily dose for a human being having 70kg body weight is 3.75-40mg. A combination of the darifenacin or its salt with an inhibitor against acetylcholinesterase (preferably donepizil or its pharmaceutically permissible salt) is especially effective. The medicament is obtained by adding an adjuvant, a diluent or a carrier to the active ingredient.
Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.